Vapreotide in Treating Patients Undergoing Elective Pancreatic Resection

Stopped early · Phase 3

Conditions studied: Pancreatic Cancer, Perioperative/Postoperative Complications

In brief

RATIONALE: Drugs such as vapreotide may prevent complications following pancreatic resection. It is not yet known if vapreotide is more effective than no further therapy in preventing side effects of pancreatic resection. PURPOSE: This randomized phase III trial is studying vapreotide to see how well it works compared to a placebo in preventing complications in patients undergoing surgery for pancreatic cancer.

Key facts

Study ID
NCT00014651
Run by
Mayo Clinic
Starts
2001-03-01
Expected to finish
2002-04-01
Last updated by the study team
2010-08-10

Who can join

Age: 18 and older, up to 90. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.